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It has been proven that organlzmg the
registries of families affected by CFS is very
helpful in research leading to: 1. Identification of
new genes of CFS, 2. Better knowledge of
correlations in CFS, 3. Identification of external
factors having impact on mutated genes, 4.
Description of mutation characteristic tor
particular populations.
Thus, development of CFS registries is very
important for increasing pre-clinical and clinical
research facilities. Direct positive consequence
will also be the improvement of quality of life by
better management ot patients affected by CFS.
Without registries these patients are very often
not identified and deprived of appropriate
recommendations concerning prophylactics,
surveillance and treatmenł. Development of
CFS registries leads also to further improvement
of quality of life by progress in management in
families with these tumours which can be
achieved by better organizing of research on
CFS. Better management in CFS tamilies
decreases also health-care costs by lowering
the number ot cancers and increasing the
number of tumours detected at their earliest
c1inical stage when the treatment is less
expensive.
The scientific objectives ot the project include:
~ elaboration ot standards tor a model cancer
family syndrome registries in Eastern Europe
- registration ot - 2000 tamilies with different
types of CFS in populations of East
European countries (Czech, Hungary, Latvia,
Lithuania, Poland)
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• initiation of European collaborative studies
with the use of material collected by East
European CFS registries.
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The role of PMRT in breast cancer patients
has been controversial. The early c1inical triais
demonstrated improvement of local-regional
control but fai led to show an improvement in
survival. Recently three randomized triais
demonstrated signiticant improvement ot overall
survival with the use ot PMRT in high risk breast
cancer patients who were also treated with
systemie adjuvant therapies. On the other hand
in several studies and in meta-analysis an
excess of non cancer, especially cardiovascular,
deaths was documented. These deaths were
probably related to high dose of radiation given
to heart and great vessels with the use of
outdated radiotherapy techniques. With the
modern radiotherapy planning it is possible to
reduce the dose to these structures. Duration of
follow-up ot patients treated with contemporary
techniques is still limited however so far no
increase ot cardiovascular deaths was found.
Great numbers ot new technical solution in
PMRT has Been recently published. According
to the available evidence PMRT should be
recommended to node positive breast cancer
patients and combined with adjuvant systemie
therapy. Chest wall and regional Iymph nodes
should be irradiated with the dose of SO Gy in
25 fractions and effort should be made to
minimize dose to heart, great vessels and lung.
The discussion on the optimal use of PMRT
continues in the literature and most important
issues include:
1) patients selection,
2) coordination of PMRT with systemie
adjuvant therapies
3) technical aspects ot radiotherapy like target
volume definition, total dose, tractionation
schedule and shielding of critical organs and
tissues. Some of this questions are
addressed by randomized studies that are
presently underway.
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